Markus Puhlmann
Chief Tech/Sci/R&D Officer at PERSPECTIVE THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Markus Puhlmann is currently the Chief Medical Officer at Perspective Therapeutics, Inc. Prior to his current position, he served as the Head-Global Clinical Development at Seagen Inc. from 2019 to 2022.
Before that, he worked as a Principal at Merck & Co., Inc. from 2015 to 2019.
Dr. Puhlmann holds a doctorate degree from Ludwig-Maximilians-Universität München and an MBA from McDonough School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-01 | 1,375,425 ( 0.23% ) | 2 M $ | 2024-03-30 |
Markus Puhlmann active positions
| Companies | Position | Start |
|---|---|---|
| PERSPECTIVE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Former positions of Markus Puhlmann
| Companies | Position | End |
|---|---|---|
| SEAGEN INC. | Corporate Officer/Principal | 2021-12-31 |
| MERCK & CO., INC. | Corporate Officer/Principal | 2018-12-31 |
Training of Markus Puhlmann
| Ludwig-Maximilians-Universität München | Doctorate Degree |
| McDonough School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Private companies | 2 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
| Perspective Therapeutics, Inc. |
- Stock Market
- Insiders
- Markus Puhlmann